DA32 Life Science Tech Acquisition registered with the SEC to offer 20 million shares at $10 each. No warrants will be included in the offering.
The new SPAC intends to pursue opportunities in the biotechnology and life science infrastructure sector.
DA32 is led by co-sponsors Deerfield Management, ARCH Venture Partners and Section 32. CEO abnd Director Steve Kafka, Ph.D., is a managing partner of Section 32, where he focuses on investments in companies operating at the confluence of life sciences and technology. Dr. Kafka has led the firm’s investments in companies including Thrive Earlier Detection, Glympse Bio, Celsius Therapeutics, and C2i Genomics.
JP Morgan and Cown are joint managers of the offering. The underwriters have a 45-day option to purchase up to 3 million additional shares to cover any over-allotments.
The SPAC has applied for a Nasdaq listing under DALS. Read more.
